Pharmacogenetic research progress of inosine triphosphate pyrophosphatase / 国际儿科学杂志

ABSTRACT

Purine drugs are for the treatment of autoimmune diseases,organ transplantation,acute lymphoblastic leukemia.The adverse reaction rate is 15％ ～ 28％,which impacts on the clinical application in recent years.Studies have shown that inosine triphosphate pyrophosphatase (ITPA) are different between individuals,and there are adverse reactions in patients with defects of ITPA when purine drugs are used.This paper reviewes the ITPA pharmacogenetic research progresses.